
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics Inc. has demonstrated steady growth in its EsoGuard test volumes, achieving a year-over-year increase of 2% in Q3 2025, highlighting a positive trend in demand for its diagnostic products. The company is expanding coverage from various payers, including Medicare, which is expected to drive revenue growth significantly as it commercializes its flagship product. Furthermore, the positive outcome of the MolDX CAC meeting positions Lucid Diagnostics favorably for future engagements, suggesting substantial upside potential and reinforcing a bullish outlook on the company's financial prospects.
Bears say
Lucid Diagnostics Inc. experienced a disappointing performance in Q3 2025, with revenue falling short of consensus estimates and a pro forma net loss of $10.3 million, slightly above expectations. The decline in EsoGuard test volume, with a decrease to 2,756 tests in Q2 from prior quarters, highlights challenges in product adoption and market penetration. Additionally, various risks, such as potential issues with insurance reimbursement, regulatory approvals, and increasing competition, contribute to a negative outlook for Lucid’s stock in the near term.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares